CASI net loss narrows to USD 20 million in H1 FY26; revenue falls 5.8% to USD 9.8 million - CASI News | RalliesCASI net loss narrows to USD 20 million in H1 FY26; revenue falls 5.8% to USD 9.8 million
C
CASI• H1 FY26 results and business update
- CASI Pharmaceuticals posted first-half 2026 revenue of USD 9.8 million, down 5.8% on a transition from EVOMELA to locally made MAFALAN.
- Net loss narrowed to USD 20 million, improving from USD 24.1 million; cash and cash equivalents fell to USD 3.8 million at June 30.
- R&D expenses dropped 37.8% to USD 2.3 million, while selling and marketing costs slid 18.5% to USD 7.5 million.
- General and administrative expenses rose 3.6% to USD 14.3 million on higher legal fees, partly offset by lower labor costs.
- Clinical progress included first patient dosed in a China Phase 1/2 CID-103 AMR trial; ITP Part A enrollment completed at 1,200 mg.
